开立医疗
(300633)
| 流通市值：143.01亿 | | | 总市值：143.01亿 |
| 流通股本：4.33亿 | | | 总股本：4.33亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 964,264,625 | 430,012,001.93 | 2,013,856,558.55 | 1,398,196,592.81 |
| 营业收入 | 964,264,625 | 430,012,001.93 | 2,013,856,558.55 | 1,398,196,592.81 |
| 二、营业总成本 | 955,582,429.16 | 444,124,458.11 | 1,893,816,500.89 | 1,351,044,835.32 |
| 营业成本 | 365,607,950.62 | 158,296,513.36 | 729,348,628.17 | 467,203,720.24 |
| 税金及附加 | 7,406,614.04 | 3,860,037.75 | 18,884,925.19 | 13,164,362.01 |
| 销售费用 | 305,029,539.07 | 140,591,287.94 | 572,889,334.62 | 458,783,435.33 |
| 管理费用 | 68,581,275.01 | 33,458,472.27 | 137,148,746.65 | 100,941,379.2 |
| 研发费用 | 244,031,119.47 | 125,724,109.43 | 472,932,714.77 | 338,307,834.78 |
| 财务费用 | -35,074,069.05 | -17,805,962.64 | -37,387,848.51 | -27,355,896.24 |
| 其中:利息费用 | 2,115,943.26 | 1,615,133.43 | 6,696,879.19 | 4,636,853.16 |
| 其中:利息收入 | 18,655,631.85 | 8,750,996.67 | 45,545,581.48 | 36,827,182.9 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 8,877.92 | 612,107.09 | 3,557,719.39 | 3,907,207.41 |
| 加:投资收益 | 2,018,513.18 | 979,152.69 | 602,699.21 | -2,487,958.79 |
| 资产处置收益 | - | - | 49,467.49 | 11,857.35 |
| 资产减值损失(新) | -13,444,560.78 | - | -112,856,288.32 | -10,117,222.04 |
| 信用减值损失(新) | -609,121.89 | -3,185,660.66 | -5,288,405.55 | -8,437,016.82 |
| 其他收益 | 37,816,656.21 | 23,278,202.77 | 115,450,700.94 | 85,674,244.83 |
| 四、营业利润 | 34,472,560.48 | 7,571,345.71 | 121,555,950.82 | 115,702,869.43 |
| 加:营业外收入 | 1,179,759.59 | 133,087.05 | 255,334.04 | 766,289.65 |
| 减:营业外支出 | 843,800.42 | 568,255.1 | 1,622,056.12 | 877,200.3 |
| 五、利润总额 | 34,808,519.65 | 7,136,177.66 | 120,189,228.74 | 115,591,958.78 |
| 减:所得税费用 | -12,221,742.03 | -938,442.86 | -22,208,147.35 | 6,606,159.31 |
| 六、净利润 | 47,030,261.68 | 8,074,620.52 | 142,397,376.09 | 108,985,799.47 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 47,030,261.68 | 8,074,620.52 | 142,397,376.09 | 108,985,799.47 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 47,030,261.68 | 8,074,620.52 | 142,397,376.09 | 108,985,799.47 |
| 扣除非经常损益后的净利润 | 39,876,707.67 | 5,998,116.17 | 110,319,389.71 | 86,116,151.45 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.11 | 0.02 | 0.33 | 0.25 |
| (二)稀释每股收益 | 0.11 | 0.02 | 0.33 | 0.25 |
| 八、其他综合收益 | -3,848,775.41 | 4,674,919.5 | -7,777,830.84 | 2,331,694.88 |
| 归属于母公司股东的其他综合收益 | -3,848,775.41 | 4,674,919.5 | -7,777,830.84 | 2,331,694.88 |
| 九、综合收益总额 | 43,181,486.27 | 12,749,540.02 | 134,619,545.25 | 111,317,494.35 |
| 归属于母公司股东的综合收益总额 | 43,181,486.27 | 12,749,540.02 | 134,619,545.25 | 111,317,494.35 |
| 公告日期 | 2025-08-22 | 2025-04-26 | 2025-04-12 | 2024-10-26 |
| 审计意见(境内) | | | 标准无保留意见 | |